FDA commissioner says drug prices are too high, calls for better evidence generation
FDA Commissioner Rob Califf told BIO CEO Rachel King on Wednesday that it’s “impossible to argue that the US is doing well in health,” highlighting high drug prices and misinformation as two key challenges.
The commissioner also took the opportunity to discuss accelerated approval reforms, attrition at the agency and the Inflation Reduction Act, which came into focus earlier this week when Merck filed a lawsuit calling parts of the drug pricing law a sham. Industry critics have argued that the legislation will have a chilling effect on innovation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.